BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 1, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 38th Annual Raymond James Institutional Investors Conference. LabCorp’s presentation is scheduled for Tuesday, March 7, 2017 at 11:00 AM (ET).
A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay.
About LabCorp®
Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is a world leading life sciences company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to provide better care. With net revenue in excess of $9 billion in 2016, LabCorp’s 50,000 employees serve clients in 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.
This press release contains forward-looking statements including with respect to estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006538/en/
Source: Laboratory Corporation of America(R) Holdings
Laboratory Corporation of America® Holdings
Investors:
Scott Frommer, 336-436-5076
[email protected]
or
Media:
Pattie Kushner, 336-436-8263
[email protected]
www.labcorp.com
